Literature DB >> 30776152

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

Taylor R Hendershott1, Delphine Zhu2, Seoni Llanes2, Cyrus P Zabetian3,4, Joseph Quinn5, Karen L Edwards6, James B Leverenz7, Thomas Montine8, Brenna Cholerton2, Kathleen L Poston2,9.   

Abstract

BACKGROUND: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD.
METHODS: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521).
RESULTS: The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%).
CONCLUSION: The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Mattis Dementia Rating Scale-2; Montreal Cognitive Assessment; Parkinson's disease; cognitive impairment

Mesh:

Year:  2018        PMID: 30776152      PMCID: PMC6532623          DOI: 10.1002/mds.27575

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  29 in total

1.  Exacerbated physical fatigue and mental fatigue in Parkinson's disease.

Authors:  J S Lou; G Kearns; B Oken; G Sexton; J Nutt
Journal:  Mov Disord       Date:  2001-03       Impact factor: 10.338

2.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

Review 3.  A review of screening tests for cognitive impairment.

Authors:  Breda Cullen; Brian O'Neill; Jonathan J Evans; Robert F Coen; Brian A Lawlor
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

4.  Evolution of mild cognitive impairment in Parkinson disease.

Authors:  M Broeders; R M A de Bie; D C Velseboer; J D Speelman; D Muslimovic; B Schmand
Journal:  Neurology       Date:  2013-06-21       Impact factor: 9.910

5.  Clinical validity of the Mattis Dementia Rating Scale in differentiating mild cognitive impairment in Parkinson's disease and normative data.

Authors:  Ondrej Bezdicek; Jiri Michalec; Tomas Nikolai; Petra Havránková; Jan Roth; Robert Jech; Evžen Růžička
Journal:  Dement Geriatr Cogn Disord       Date:  2015-03-18       Impact factor: 2.959

6.  What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?

Authors:  Pietro Tiraboschi; David P Salmon; Lawrence A Hansen; Richard C Hofstetter; Leon J Thal; Jody Corey-Bloom
Journal:  Brain       Date:  2006-01-09       Impact factor: 13.501

7.  The MoCA: well-suited screen for cognitive impairment in Parkinson disease.

Authors:  J C Dalrymple-Alford; M R MacAskill; C T Nakas; L Livingston; C Graham; G P Crucian; T R Melzer; J Kirwan; R Keenan; S Wells; R J Porter; R Watts; T J Anderson
Journal:  Neurology       Date:  2010-11-09       Impact factor: 9.910

8.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Authors:  S Hoops; S Nazem; A D Siderowf; J E Duda; S X Xie; M B Stern; D Weintraub
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

9.  The NINDS Parkinson's disease biomarkers program.

Authors:  Liana S Rosenthal; Daniel Drake; Roy N Alcalay; Debra Babcock; F DuBois Bowman; Alice Chen-Plotkin; Ted M Dawson; Richard B Dewey; Dwight C German; Xuemei Huang; Barry Landin; Matthew McAuliffe; Vladislav A Petyuk; Clemens R Scherzer; Coryse St Hillaire-Clarke; Beth-Anne Sieber; Margaret Sutherland; Chi Tarn; Andrew West; David Vaillancourt; Jing Zhang; Katrina Gwinn
Journal:  Mov Disord       Date:  2015-10-07       Impact factor: 10.338

Review 10.  Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.

Authors:  Matej Skorvanek; Jennifer G Goldman; Marjan Jahanshahi; Connie Marras; Irena Rektorova; Ben Schmand; Erik van Duijn; Christopher G Goetz; Daniel Weintraub; Glenn T Stebbins; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2017-11-23       Impact factor: 10.338

View more
  7 in total

1.  Freezing of gait is a risk factor for cognitive decline in Parkinson's disease.

Authors:  Yi Qu; Jiangting Li; Yupeng Chen; Jingyi Li; Qixiong Qin; Danlei Wang; Jingwei Zhao; Qingmei Yang; Zhijuan Mao; Yongjie Xiong; Zhe Min; Zheng Xue
Journal:  J Neurol       Date:  2022-09-27       Impact factor: 6.682

2.  Multiculturalism: A Challenge for Cognitive Screeners in Parkinson's Disease.

Authors:  Marta Statucka; Kirsten Cherian; Alfonso Fasano; Renato P Munhoz; Melanie Cohn
Journal:  Mov Disord Clin Pract       Date:  2021-05-27

3.  Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ.

Authors:  Pardis Zarifkar; Jeehyun Kim; Christian La; Kai Zhang; Sophie YorkWilliams; Taylor F Levine; Lu Tian; Per Borghammer; Kathleen L Poston
Journal:  Parkinsonism Relat Disord       Date:  2021-01-12       Impact factor: 4.402

4.  Comparison of Montreal cognitive assessment and Mattis dementia rating scale in the preoperative evaluation of subthalamic stimulation in Parkinson's disease.

Authors:  Eileen Gülke; Mohammad Alsalem; Maja Kirsten; Eik Vettorazzi; Chi-Un Choe; Ute Hidding; Simone Zittel-Dirks; Carsten Buhmann; Miriam Schaper; Alessandro Gulberti; Christian K E Moll; Wolfgang Hamel; Johannes Koeppen; Christian Gerloff; Monika Pötter-Nerger
Journal:  PLoS One       Date:  2022-04-07       Impact factor: 3.240

5.  Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease.

Authors:  Lijie Wang; Xiaoqin Tang
Journal:  Comput Math Methods Med       Date:  2022-07-18       Impact factor: 2.809

6.  Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.

Authors:  Edward N Wilson; Michelle S Swarovski; Patricia Linortner; Marian Shahid; Abigail J Zuckerman; Qian Wang; Divya Channappa; Paras S Minhas; Siddhita D Mhatre; Edward D Plowey; Joseph F Quinn; Cyrus P Zabetian; Lu Tian; Frank M Longo; Brenna Cholerton; Thomas J Montine; Kathleen L Poston; Katrin I Andreasson
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

7.  White Matter Hyperintensities Related to Parkinson's Disease Executive Function.

Authors:  Patricia Linortner; Colin McDaniel; Marian Shahid; Taylor F Levine; Lu Tian; Brenna Cholerton; Kathleen L Poston
Journal:  Mov Disord Clin Pract       Date:  2020-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.